Low frequency of mismatch repair deficiency in gallbladder cancer by Goeppert, Benjamin et al.
RESEARCH Open Access
Low frequency of mismatch repair
deficiency in gallbladder cancer
Benjamin Goeppert1,2*, Stephanie Roessler1,2, Marcus Renner1, Moritz Loeffler1, Stephan Singer1, Melina Rausch1,
Thomas Albrecht1,2, Arianeb Mehrabi2,3, Monika Nadja Vogel4, Anita Pathil5, Elena Czink2,6, Bruno Köhler2,6,
Christoph Springfeld2,6, Christian Rupp2,6, Karl Heinz Weiss2,5, Peter Schirmacher1,2,
Magnus von Knebel Doeberitz7 and Matthias Kloor7
Abstract
Background: DNA mismatch repair (MMR) deficiency is a major pathway of genomic instability in cancer. It leads
to the accumulation of numerous mutations predominantly at microsatellite sequences, a phenotype known as
microsatellite instability (MSI). MSI tumors have a distinct clinical behavior and commonly respond well to immune
checkpoint blockade, irrespective of their origin. Data about the prevalence of MSI among gallbladder cancer (GBC)
have been conflicting. We here analyzed a well-characterized cohort of 69 Western-world GBCs.
Methods: We analyzed the mononucleotide MSI marker panel consisting of BAT25, BAT26, and CAT25 to determine
the prevalence of MMR deficiency-induced MSI.
Results: MSI was detected in 1/69 (1.4%) of analyzed GBCs. The detected MSI GBC had a classical histomorphology,
i.e. of acinar/tubular/glandular pancreatobiliary phenotype, and showed nuclear expression of all four MMR proteins
MLH1, MSH2, MSH6, and PMS2. The MSI GBC patient showed a prolonged overall survival, despite having a high
tumor stage at diagnosis. The patient had no known background or family history indicative of Lynch syndrome.
Conclusions: Even though the overall number of MSI tumors is low in GBC, the potentially therapeutic benefit of
checkpoint blockade in the respective patients may justify MSI analysis of GBC.
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Introduction
The incidence of DNA mismatch repair (MMR)-defi-
cient, microsatellite-unstable (MSI) tumors is of particu-
lar clinical relevance since it has been shown that
MMR-deficient tumors are more responsive to immune
checkpoint blockade, particularly using antibodies di-
rected against the immune checkpoint PD-1 or PD-L1
[1], than MMR-proficient tumors. Histomorphologi-
cally, gallbladder cancer (GBC) is a diverse group of tu-
mors, most often displaying phenotypes of an
adenocarcinoma. Clinically, GBC is often treated to-
gether with cholangiocarcinomas (CCAs) as biliary tract
cancers and thus as one disease, although genetic
heterogeneity as well as differences in clinical behavior is
nowadays widely acknowledged [2]. Most patients with
GBC present with unresectable or metastatic disease.
Despite systemic chemotherapy, prognosis remains poor
and to date there are no established molecular targeted
therapies tailored to GBC [3]. Molecular events occur-
ring during the development of biliary tract cancers
(BTC) are heterogeneous and likely follow a multistep
process encompassing alterations of several oncogenes
and tumor suppressor genes, such as KRAS, TP53,
EGFR, and ERBB2/3. The genomic spectra of BTC have
been previously nicely depicted [4], and we have recently
demonstrated the presence of MSI in a small proportion
(4/308; 1.3%) of CCAs [5].
So far, there are no systematic data available informing
about the prevalence of DNA mismatch repair deficiency
and MSI in GBC. Previous studies on MSI in biliary
tract cancers have reported MMR deficiency and MSI in
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up to 30% of cases, particularly in liver-fluke-associated
CCA specimens from endemic regions in Thailand [6].
For GBC, reported proportions of MSI tumors also var-
ied greatly, because of a high diversity of marker panels
used for determining MSI.
In the present study, we aimed to determine frequency
and clinicopathological characteristics of MSI tumors in
a well-characterized German cohort of GBC.
Methods
Clinicopathological characteristics of gallbladder
carcinoma patients
Resection specimens from 69 patients (mean age: 69.8
years, median age: 71.4 years) who underwent hepatobili-
ary surgery at the University Hospital Heidelberg between
1995 and 2010 were included in this study. The GBC co-
hort consisted only of adenocarcinomas, including all
histologic variants. None of the patients received radio-
and/or chemotherapy prior to surgery. Tumors were
restaged according to the 8th TNM Classification of Ma-
lignant Tumors and classified according to the current
World Health Organization (WHO) tumor classification
system (WHO Classification of Tumours of the Digestive
System, 4th Ed., 2010) by two experienced pathologists,
i.e. consultant pathologists of our institute with a
specialization in hepatobiliary pathology (BG and SS). A
summary of clinicopathological data is given in Table 1.
The use of the tissues for this study was approved by the
institutional ethics committee (206/05).
Tissue microarray construction
From all 69 GBC FFPE tissue blocks, 3 μm sections were
cut and stained with H&E. Representative areas were
marked by experienced pathologists (BG and SS). For
each case, tumor tissue cores (1.0 mm diameter) from
the selected representative tumor areas were punched
out of the sample tissue blocks and embedded into a
new paraffin array block using a tissue microarrayer
(Beecher Instruments, Woodland, CA, USA).
Table 1 Clinicopathological data of the gallbladder carcinoma
cohort with complete clinicopathological data and correlation to
the MSI status (n = 69)
All GBC
patients
Number (percent Number (percent) Number (percent)
total non-MSI MSI
69 (100.0) 68 (98.6) 1 (1.4)
Agea
< 69.8 yrs 28 (40.6) 27 (39.1) 1 (1.4)
> 69.8 yrs 41 (59.4) 41 (59.4) 0 (0.0)
Sex
m 21 (30.4) 21 (30.4) 0 (0.0)
w 48 (69.6) 47 (68.1) 1 (1.4)
pT
T1 5 (7.2) 5 (7.2) 0 (0.0)
T2 30 (43.5) 29 (42.0) 1 (1.4)
T3 26 (37.7) 26 (37.7) 0 (0.0)
T4 8 (11.6) 8 (11.6) 0 (0.0)
pN
N0 13 (18.8) 13 (18.8) 0 (0.0)
N1 19 (27.5) 18 (26.1) 1 (1.4)
Nx 37 (53.6) 37 (53.6) 0 (0.0)
M
M0 56 (81.2) 55 (79.7) 1 (1.4)
M1 13 (18.8) 13 (18.8) 0 (0.0)
UICCb
UICC 2 5 (7.2) 5 (7.2) 0 (0.0)
UICC 3 18 (26.1) 17 (24.6) 1 (1.4)
UICC 4 18 (26.1) 18 (26.1) 0 (0.0)
NA 28 (40.6) 28 (40.6) 0 (0.0)
G
G1 4 (5.8) 4 (5.8) 0 (0.0)
G2 41 (59.4) 40 (58.0) 1 (1.4)
G3 24 (34.8) 24 (34.8) 0 (0.0)
L
L0 42 (60.9) 42 (60.9) 0 (0.0)
L1 27 (39.1) 26 (37.7) 1 (1.4)
V
V0 53 (76.8) 52 (75.4) 1 (1.4)
V1 16 (23.2) 16 (23.2) 0 (0.0)
Pn
Pn0 50 (72.5) 50 (72.5) 0 (0.0)
Pn1 19 (27.5) 18 (26.1) 1 (1.4)
Histology
ductal 48 (69.6) 47 (68.1) 1 (1.4)
papillary 6 (8.7) 6 (8.7) 0 (0.0)
mucinous 8 (11.6) 8 (11.6) 0 (0.0)
intestinal 1 (1.4) 1 (1.4) 0 (0.0)
Table 1 Clinicopathological data of the gallbladder carcinoma
cohort with complete clinicopathological data and correlation to
the MSI status (n = 69) (Continued)
All GBC
patients
Number (percent Number (percent) Number (percent)
total non-MSI MSI
69 (100.0) 68 (98.6) 1 (1.4)
other 6 (8.7) 6 (8.7) 0 (0.0)
aMedian patients’ age was 71.4 years and mean age was 69.8 years; bCases
with pNx had no lymph nodes resected, therefore, UICC status could not
be assessed
pT Pathology-based tumor stage, pN Pathology-based nodal status, M Distant
metastasis status, UICC Tumor stage, G Tumor grade, L Lymph vessel invasion,
V Blood vessel invasion, Pn Perineural invasion. The 6 tumors listed in the
histology section as „other “are 3 adenosquamous carcinomas, 2 signet ring
carcinomas, and 1 clear-cell adenocarcinoma
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Immunohistochemical staining of MMR proteins
Immunohistochemical analyses were performed on 3 μm
thick sections in all tumors classified as MSI by
PCR-based methods. Briefly, the slides were pretreated
by boiling for 10 min with a microwave in target re-
trieval buffer (pH 9, Dako, Hamburg, Germany) before
application of monoclonal antibodies specific for MSH2
(clone FE11, dilution 1:100, Calbiochem, Darmstadt,
Germany), MLH1 (clone G168–15, 1:100, BD Biosci-
ences, San Diego, CA, USA), MSH6 (clone 44; 1:200; BD
Biosciences, San Diego, CA, USA), and PMS2 (clone
EPR3947, ready to use; Cell Marque, Sigma Aldrich, St.
Louis, Missouri, USA). An immunoperoxidase method
was used to visualize bound antibodies with DAB
(3-amino-9-ethylcarbazole, Dako) as chromogen.
Molecular microsatellite instability analysis
DNA was extracted using the DNeasy Blood and Tissue
kit (Qiagen, Hilden, Germany) and eluted in pure water.
PCR with fluorescence-labelled oligonucleotides was per-
formed to amplify the mononucleotide markers BAT25,
BAT26, and CAT25 from tumor tissue DNA as described
previously [7]. From the tumor classified as MSI, in
addition BAT40 was amplified, using the oligonucleotide
primers 5′-ATTAACTTCCTACACCACAAC-3′ and
5′-gTAgAgCAAgACCACCTTg-3′. Amplified fragments
were visualized on an ABI3130xl genetic analyzer (Applied
Biosystems, Darmstadt, Germany) to detect potential
length alterations of the microsatellites. Fragment sizes
differing from the normal range of allelic size variation
known for the amplicons encompassing BAT25 (108–110
bp), BAT26 (116–118 bp), and CAT25 (146–148 bp) were
regarded as MSI [7]. Tumors showing such amplicons in
two or more markers were classified as MSI.
Statistical analyses including correlation analyses with
other immunohistochemical variables
Statistical analyses were performed with the statistical
computing environment R version 3.0.1. Correlation
analyses of MSI status with clinicopathological and other
immunohistochemical variables were assessed with Fish-
er’s exact test. Due to the low number of detected MSI
cases, a statistical correlation analysis was not feasible
for all given parameters. Univariate survival analysis was
performed for overall survival by generation of
Kaplan-Meier curves using GraphPad Prism 6. Signifi-
cance of differences between the groups was assessed
using the Log-rank-test. P values < 0.05 were considered
significant. Data concerning expression of PD-L1, MHC
I, quantity and quality of tumor infiltrating immune
cells, as well as proliferation index (Ki-67) were available
partly from previously published studies [8, 9].
Results
Frequency of microsatellite instability in gallbladder
carcinoma
All cases were tested for MSI status using a highly sensi-
tive mononucleotide marker panel (BAT25, BAT26,
CAT25), which specifically detects DNA mismatch repair
deficiency-induced alterations at long mononucleotide re-
peats [7, 10]. One (1.4%) out of 69 analyzed GBCs showed
MSI at all three markers, whereas no aberrant peaks were
detected in the remaining 68 tumor specimens. MSI status
was confirmed by repeating the analysis from independ-
ently isolated tumor DNA and corresponding non-tumor
DNA from the same paraffin block, and by testing BAT40
as an additional marker (Fig. 1). Immunohistochemistry
for DNA mismatch repair proteins MLH1, PMS2, MSH2,
and MSH6 revealed no loss of nuclear immunoreactivity
for all tested repair proteins (Fig. 2).
Clinicopathological data of MSI gallbladder carcinoma
and patient survival
The detected MSI GBC had a typical histomorphology,
i.e. showing the typical acinar/tubular/glandular (NOS)
pancreatobiliary phenotype (Fig. 2 and Additional file 1:
Figure S1). Furthermore, the MSI patient was female,
belonged to the younger patient group (age at diagnosis:
Fig. 1 Results of microsatellite instability analysis. Peak patterns of the MSI tumor analyzed by the GeneMapper Software (version 5, Applied
Biosystems) show aberrant peak profiles indicative of MSI in all 4 tested mononucleotide markers. Highest peaks in MSI profiles obtained from
normal tissue are marked by asterisks (upper panel). Aberrant peaks detected in tumor tissue are marked by red arrows (lower panel)
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68 years, not significant different to mean age of the en-
tire GBC cohort: 69.8 years), showed a positive lymph
node status (pN1) and a high UICC stage (UICC stage 3;
Table 1). Nevertheless, the MSI GBC patient showed an
overall survival of 4.5 years after surgery, compared to a
median OS in patients with non-MSI tumors of 1.6
years.
Immune phenotype of microsatellite-unstable gallbladder
carcinoma
MSI tumors commonly present with a high density of
local immune cell infiltration and expression of immune
checkpoint molecules. We analyzed the quantity and
quality of tumor infiltrating immune cells, MHC class I,
PD-L1, and HER2-status in the same GBC cohort [8, 9].
In the MSI GBC, a high expression of MHC class I anti-
gen on the tumor cell surface could be detected (Table
2), while numbers of tumor-infiltrating immune cells
were within the range of non-MSI cases of the cohort.
The MSI GBC showed no PD-L1 expression, neither on
the tumor cell surface nor on tumor-associated inflam-
matory cells. The proliferation index (Ki-67) was low
(6%). Due to only one MSI GBC detected in this cohort,
statistical correlation analyses for clinicopathological pa-
rameters and immune characteristics were not feasible.
Table 2 MSI vs non-MSI gallbladder carcinomas with regard to
MHC class I immunoreactivity
MHC score all GBC cases MSI neg MSI pos
0 6 6 0
1 2 2 0
2 3 3 0
3 7 7 0
4 8 8 0
6 5 5 0
8 18 17 1
9 2 2 0
12 8 8 0
NA 10 10 0
total 69 68 1
Fig. 2 Histology and immunohistochemistry of the detected MSI gallbladder
carcinoma. a: Hematoxylin & Eosin (HE) staining of a full-slide section
of the detected MSI GBC shows a typical ductal morphology of
pancreatobiliary subtype (representative atypical neoplastic ducts
are indicated by arrows, original magnification: 20x). b-e:
Immunohistochemistry of MMR proteins showed retained nuclear
signals in the neoplastic epithelia (MLH1, PMS2, MSH2, and
MSH6; original magnification: 100x)
Goeppert et al. Diagnostic Pathology           (2019) 14:36 Page 4 of 6
Discussion
In summary, our study demonstrates that MMR
deficiency-induced MSI is rare in this well-characterized,
non-liver-fluke associated German GBC cohort (n = 69).
The lower frequency of MSI in our study compared to
several others may be explained, as previously demon-
strated for CCA, but also for GBC [10–16], by regional
differences and associated pathogenetic mechanisms. In
addition, in the present study we exclusively used mono-
nucleotide repeats, which are more specific for detecting
DNA mismatch repair deficiency-induced MSI than di-
or tetranucleotide markers [17, 18], thereby avoiding
false positive results due to incidental slippage events in
MMR-proficient cells. Such events may explain the high
rates of MSI in the literature, which in a recent retro-
spective literature analysis article was 18 out of 357 (5%)
in GBC [19].
In our analysis, only one (1.4%) out of 69 tumors
showed instability affecting all the sensitive mononucleo-
tide markers BAT25, BAT26, and CAT25. As immuno-
histochemistry did not show loss of any of the four
MMR proteins analyzed, MSI analysis was repeated
twice from independent tissue blocks and TMA cores,
and the MSI status was confirmed. MSI tumors present-
ing with retained expression of MMR proteins are rare,
but have been previously reported in the literature [20,
21]. Possible reasons for such a discrepancy may be
somatic missense mutations in DNA mismatch repair
genes that result in the expression of a non-functional
MMR protein, or, as reported recently, mutations in
other MMR-related genes such as the exonuclease do-
main of the POLE gene [20, 21]. Further analysis such as
exome or whole genome sequencing of tumor tissue
would have been required to identify the molecular
mechanisms leading to MSI and to inform about a pos-
sible hereditary background. Unfortunately, in our case
complete somatic mutation analysis of MMR genes was
not feasible due to limited amounts of available tumor
DNA from FFPE tissue specimens.
The classical MSI phenotype including a special
MSI histology with poor differentiation and dense
lymphocyte infiltration, which is known from MSI
colorectal cancers [22–24], was not fully recapitulated
in the detected MSI GBC. However, in line with the
improved prognosis commonly reported to be associ-
ated with tumors of the MSI phenotype, the patient’s
overall survival was 4.5 years, compared to a median
overall survival of 1.6 years in the MSS group of the
same stage (UICC 3). Due to the limited number
of patients, a statistical analysis of potential survival
benefits related to MSI in GBC was not feasible. A
recent study, however, did not report a prolonged
survival in MSI compared to non-MSI GBC patients
[10].
Although the overall frequency of MSI in GBC is low
with less than 2% in the present cohort, MSI testing of
GBC should be considered if the patient has a chance to
benefit from immune checkpoint blockade [25]. Recent
studies demonstrated that patients with MSI BTC in fact
may show significant clinical responses towards treat-
ment with anti-PD-1 or anti-PD-L1 antibodies [1, 26].
Interestingly, even BTC patients with far progressed dis-
ease status that are therapy-refractory against che-
motherapeutical agents commonly used in the treatment
of BTC can show significant treatment responses upon
immune checkpoint blockade using pembrolizumab
[27]. Although we cannot state, whether MSI in GBC is
associated with an increased immune infiltration due to
limited patient numbers, considering the pronounced
and sustainable benefit reported for advanced MSI can-
cer patients after treatment with immune checkpoint in-
hibitors, additional studies are strongly encouraged that
use PCR-based MSI testing in parallel with MMR pro-
tein IHC prospectively in larger series of GBC.
Concerning MSI testing in GBC patients, this study
has several clinical implications: i) it demonstrates that
the frequency of MSI is low in Western-world GBC, and
ii) PCR-based MSI analysis using mononucleotide
markers should be considered due to their sensitivity
and specificity for the detection of MMR
deficiency-induced MSI, particularly in GBC patients
who might be eligible for immune checkpoint blockade.
Conclusions
The frequency of MMR deficiency-induced MSI among
Western-world gallbladder cancers is low. However, due
to the significant clinical responses of MSI tumor pa-
tients towards immune checkpoint blockade, MSI ana-
lysis should be considered in this tumor type.
Additional file
Additional file 1: Figure S1. Histology of the detected MSI gallbladder
carcinoma. High magnification pictures of Hematoxylin & Eosin (HE)
stained full-slide sections of the detected MSI GBC show a typical
glandular, tubular, acinar, ductal morphology of pancreatobiliary subtype
(A: original magnification: 200x and B: 400x). (DOCX 348 kb)
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